Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides
- PMID: 24938782
- PMCID: PMC4084462
- DOI: 10.1073/pnas.1401564111
Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides
Abstract
The two major forms of the amyloid-beta (Aβ) peptide found in plaques in patients suffering from Alzheimer's disease, Aβ40 and Aβ42, only differ by two amino acids in the C-terminal region, yet they display markedly different aggregation behavior. The origins of these differences have remained challenging to connect to specific molecular-level processes underlying the aggregation reaction. In this paper we use a general strategy to apply the conventional workflow of chemical kinetics to the aggregation of the Aβ40 peptide to identify the differences between Aβ40 and Aβ42 in terms of the microscopic determinants of the aggregation reaction. Our results reveal that the major source of aggregates in the case of Aβ40 is a fibril-catalyzed nucleation process, the multistep nature of which is evident through its saturation behavior. Moreover, our results show that the significant differences in the observed behavior of the two proteins originate not simply from a uniform increase in all microscopic rates for Aβ42 compared with Aβ40, but rather are due to a shift of more than one order of magnitude in the relative importance of primary nucleation versus fibril-catalyzed secondary nucleation processes. This analysis sheds light on the microscopic determinants of the aggregation behavior of the principal forms of Aβ and outlines a general approach toward achieving an understanding at the molecular level of the aberrant deposition of insoluble peptides in neurodegenerative disorders.
Keywords: aggregation mechanism; neurodegeneration; protein aggregation; rate law.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Ca(2+), within the physiological concentrations, selectively accelerates Abeta42 fibril formation and not Abeta40 in vitro.Biochim Biophys Acta. 2009 Oct;1794(10):1537-48. doi: 10.1016/j.bbapap.2009.06.022. Epub 2009 Jul 10. Biochim Biophys Acta. 2009. PMID: 19595795
-
Cross-seeding between Aβ40 and Aβ42 in Alzheimer's disease.FEBS Lett. 2017 Jan;591(1):177-185. doi: 10.1002/1873-3468.12526. Epub 2016 Dec 29. FEBS Lett. 2017. PMID: 27981583 Free PMC article.
-
A new structural model of Alzheimer's Aβ42 fibrils based on electron paramagnetic resonance data and Rosetta modeling.J Struct Biol. 2016 Apr;194(1):61-7. doi: 10.1016/j.jsb.2016.01.013. Epub 2016 Jan 28. J Struct Biol. 2016. PMID: 26827680 Free PMC article.
-
Effects of Cu(II) on the aggregation of amyloid-β.J Biol Inorg Chem. 2019 Dec;24(8):1197-1215. doi: 10.1007/s00775-019-01727-5. Epub 2019 Oct 10. J Biol Inorg Chem. 2019. PMID: 31602542 Review.
-
Aβ42 and Aβ40: similarities and differences.J Pept Sci. 2015 Jul;21(7):522-9. doi: 10.1002/psc.2789. Epub 2015 May 28. J Pept Sci. 2015. PMID: 26018760 Review.
Cited by
-
Characterization of full-length p53 aggregates and their kinetics of formation.Biophys J. 2022 Nov 15;121(22):4280-4298. doi: 10.1016/j.bpj.2022.10.013. Epub 2022 Oct 13. Biophys J. 2022. PMID: 36230002 Free PMC article.
-
Repurposing Anidulafungin for Alzheimer's Disease via Fragment-Based Drug Discovery.ACS Chem Neurosci. 2024 Aug 21;15(16):2995-3008. doi: 10.1021/acschemneuro.4c00150. Epub 2024 Aug 3. ACS Chem Neurosci. 2024. PMID: 39096284 Free PMC article.
-
Key Residues for the Formation of Aβ42 Amyloid Fibrils.ACS Omega. 2018 Jul 31;3(7):8401-8407. doi: 10.1021/acsomega.8b00887. ACS Omega. 2018. PMID: 30087945 Free PMC article.
-
Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid.Commun Biol. 2019 Oct 8;2:365. doi: 10.1038/s42003-019-0612-2. eCollection 2019. Commun Biol. 2019. PMID: 31602414 Free PMC article.
-
Tuning the rate of aggregation of hIAPP into amyloid using small-molecule modulators of assembly.Nat Commun. 2022 Feb 24;13(1):1040. doi: 10.1038/s41467-022-28660-7. Nat Commun. 2022. PMID: 35210421 Free PMC article.
References
-
- Dobson CM. Protein folding and misfolding. Nature. 2003;426(6968):884–890. - PubMed
-
- Aguzzi A, Haass C. Games played by rogue proteins in prion disorders and Alzheimer’s disease. Science. 2003;302(5646):814–818. - PubMed
-
- Aguzzi A, O’Connor T. Protein aggregation diseases: Pathogenicity and therapeutic perspectives. Nat Rev Drug Discov. 2010;9(3):237–248. - PubMed
-
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
